金水定喘丸联合黄芪注射液穴位注射对肺肾两虚型哮喘-慢性阻塞性肺疾病重叠患者肺功能、FeNO及炎性因子的影响OA
Effects of Jinshui Dingchuan pills combined with acupoint injection of astragalus injection on lung function,FeNO,and inflammatory factors in patients with asthma-COPD overlap with syndrome of lung-kidney deficiency
目的 观察金水定喘丸联合黄芪注射液穴位注射治疗肺肾两虚型哮喘-慢性阻塞性肺疾病重叠(ACO)患者疗效及对肺功能、呼出气一氧化氮(FeNO)、血清炎性标志物水平的影响.方法 采用随机数字表法,将2023 年8 月—2024 年10 月于中国中医科学院西苑医院济宁医院肺病科治疗的60 例 ACO 患者随机分配至治疗组与对照组,每组30 例.对照组患者采用布地奈德福莫特罗粉吸入剂联合噻托溴铵粉吸入剂治疗,治疗组在对照组治疗基础上联用金水定喘丸口服及黄芪注射液关元、足三里穴位注射,2 组疗程均为12 周.比较2 组患者治疗前后中医证候评分、哮喘控制测试(ACT)评分、慢性阻塞性肺疾病评估测试(CAT)评分、第1 秒用力呼气量占预计值百分比(FEV1%)、第 1 秒用力呼气量(FEV1)/用力肺活量(FVC)、FeNO 及血清 C 反应蛋白(CRP)、白细胞介素-6(IL-6)、总免疫球蛋白 E(IgE)水平和嗜酸性粒细胞占白细胞总数的百分比(EOS%),评估2 组临床疗效.结果 最终对照组29 例、治疗组30 例完成研究.治疗后2 组中医证候评分、CAT 评分及 FeNO、CRP、IL-6、总 IgE、EOS%均较治疗前明显降低,ACT 评分及FEV1%、FEV1/FVC 均较治疗前明显升高,且治疗组中医证候评分、CAT 评分及 FeNO、CRP、IL-6、总 IgE、EOS%均明显低于对照组,ACT 评分及 FEV1%、FEV1/FVC 均明显高于对照组,差异均有统计学意义(P 均<0.05).治疗组总有效率明显高于对照组[90.0%(27/30)比69.0%(20/29),P<0.05].结论 金水定喘丸联合黄芪注射液穴位注射治疗肺肾两虚型 ACO 能明显减轻临床症状,改善患者肺功能,抑制气道炎症反应,提高患者生活质量.
Objective It is to evaluate the efficacy of Jinshui Dingchuan pills combined with acupoint injection of as-tragalus injection in the treatment of patients with asthma-chronic obstructive pulmonary disease overlap(ACO)with syn-drome of lung-kidney deficiency,and to observe its effects on pulmonary function,exhaled nitric oxide(FeNO),and ser-um levels of inflammatory markers.Methods Sixty patients with ACO treated at the Department of Pulmonology of Jining Hospital of Xiyuan Hospital of China Academy of Chinese Medical Sciences from August 2023 to October 2024 were ran-domly divided into treatment group and control group by a random number table,with 30 patients in each group.The pa-tients in the control group were treated with a combination of budesonide/formoterol powder for inhalation and tiotropium bromide powder for inhalation,the treatment group was treated with Jinshui Dingchuan pills via oral administration com-bined with astragalus injection via acupoint injection at Guanyuan and Zusanli acupoints on the basis of treatment in the control group,both groups were treated for 12 weeks.The TCM syndrome scores,ACT scores,CAT scores,FEV1%,FEV1/FVC,FeNO,and serum levels of CRP,IL-6,IgE,and EOS%of patients before and after treatment were compared between the two groups,and the clinical efficacies of the two groups were evaluated.Results A total of 29 patients in the control group and 30 patients in the treatment group finally completed the study.After treatment,the TCM syndrome scores,CAT scores,and the levels of FeNO,CRP,IL-6,total IgE,and EOS%were all significantly lower,while the ACT scores,FEV1%,and FEV1/FVC were all significantly higher than those before treatment in the two groups,further-more,the TCM syndrome scores,CAT scores,the levels of FeNO,CRP,IL-6,total IgE,and EOS%were all significantly lower,while the ACT scores,FEV1%,and FEV1/FVC were significantly higher in the treatment group than those in the control group,the differences were all statistically significant(all P<0.05).The overall response rate in the treatment group was significantly higher than that in the control group[90.0%(27/30)vs69.0%(20/29),P<0.05].Conclu-sion Jinshui Dingchuan pills combined with acupoint injection of astragalus injection can significantly alleviate clinical symptoms,improve lung function,inhibit airway inflammatory responses,and improve quality of life in the treatment of ACO patients with syndrome of lung-kidney deficiency.
程娜娜;刘威;颜廷龙
中国中医科学院西苑医院济宁医院,山东 济宁 272000中国中医科学院西苑医院济宁医院,山东 济宁 272000中国中医科学院西苑医院济宁医院,山东 济宁 272000
医药卫生
哮喘-慢性阻塞性肺疾病重叠金水定喘丸黄芪注射液穴位注射肺功能呼出气一氧化氮炎性因子
asthma-chronic obstructive pulmonary disease overlapJinshui Dingchuan pillsastragalus injectionacu-point injectionlung functionEeNOinflammatory factors
《现代中西医结合杂志》 2026 (8)
1061-1066,6
山东省中医药科技项目面上项目(M-2023125)
评论